These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 19053784)

  • 21. A simple and powerful flow cytometric method for the simultaneous determination of multiple parameters at G protein-coupled receptor subtypes.
    Schneider E; Mayer M; Ziemek R; Li L; Hutzler C; Bernhardt G; Buschauer A
    Chembiochem; 2006 Sep; 7(9):1400-9. PubMed ID: 16888730
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neuropeptide Y as a partial agonist of the Y1 receptor.
    Sah R; Balasubramaniam A; Parker MS; Sallee F; Parker SL
    Eur J Pharmacol; 2005 Nov; 525(1-3):60-8. PubMed ID: 16293244
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The identification and optimisation of novel and selective diamide neuropeptide Y Y2 receptor antagonists.
    Lunniss GE; Barnes AA; Barton N; Biagetti M; Bianchi F; Blowers SM; Caberlotto L; Emmons A; Holmes IP; Montanari D; Norris R; Walters DJ; Watson SP
    Bioorg Med Chem Lett; 2009 Aug; 19(15):4022-5. PubMed ID: 19581086
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fluorescence- and luminescence-based methods for the determination of affinity and activity of neuropeptide Y2 receptor ligands.
    Ziemek R; Brennauer A; Schneider E; Cabrele C; Beck-Sickinger AG; Bernhardt G; Buschauer A
    Eur J Pharmacol; 2006 Dec; 551(1-3):10-8. PubMed ID: 17027743
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Human neuropeptide YY1 receptors exert unequal control of the extracellular acidification rate in different cell lines.
    Van Liefde I; Vanderheyden PM; Fraeyman N; De Backer JP; Vauquelin G
    Eur J Pharmacol; 1998 Apr; 346(1):87-95. PubMed ID: 9617757
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Optimization of a series of 2,4-diaminopyridines as neuropeptide Y Y1 receptor antagonists with reduced hERG activity.
    Kameda M; Kobayashi K; Ito H; Miyazoe H; Tsujino T; Nakama C; Kawamoto H; Ando M; Ito S; Suzuki T; Kanno T; Tanaka T; Tahara Y; Tani T; Tanaka S; Tokita S; Sato N
    Bioorg Med Chem Lett; 2009 Aug; 19(15):4325-9. PubMed ID: 19487123
    [TBL] [Abstract][Full Text] [Related]  

  • 27. NPY Y1 antagonists: structure-activity relationships of arginine derivatives and hybrid compounds with arpromidine-like partial structures.
    Aiglstorfer I; Uffrecht A; Gessele K; Moser C; Schuster A; Merz S; Malawska B; Bernhardt G; Dove S; Buschauer A
    Regul Pept; 1998 Sep; 75-76():9-21. PubMed ID: 9802389
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Co-expression of neuropeptide Y Y1 and Y5 receptors results in heterodimerization and altered functional properties.
    Gehlert DR; Schober DA; Morin M; Berglund MM
    Biochem Pharmacol; 2007 Dec; 74(11):1652-64. PubMed ID: 17897631
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [3H]HEMADO--a novel tritiated agonist selective for the human adenosine A3 receptor.
    Klotz KN; Falgner N; Kachler S; Lambertucci C; Vittori S; Volpini R; Cristalli G
    Eur J Pharmacol; 2007 Feb; 556(1-3):14-8. PubMed ID: 17126322
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vivo inhibition of neuropeptide FF agonism by BIBP3226, an NPY Y1 receptor antagonist.
    Fang Q; Guo J; He F; Peng YL; Chang M; Wang R
    Peptides; 2006 Sep; 27(9):2207-13. PubMed ID: 16762456
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preparation of fluorescent nonpeptidic neuropeptide Y receptor ligands: analogues of the quinazoline-type anti-obesity Y5 antagonist CGP 71683A.
    Li L; Mayer M; Schneider E; Schreiber E; Bernhardt G; Peng S; Buschauer A
    Arch Pharm (Weinheim); 2003 Dec; 336(12):585-90. PubMed ID: 14677152
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evidence for the existence of an additional class of neuropeptide Y receptor sites in rat brain.
    Dumont Y; Moyse E; Fournier A; Quirion R
    J Pharmacol Exp Ther; 2005 Oct; 315(1):99-108. PubMed ID: 15947033
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Establishment of robust functional assays for the characterization of neuropeptide Y (NPY) receptors: identification of 3-(5-benzoyl-thiazol-2-ylamino)-benzonitrile as selective NPY type 5 receptor antagonist.
    Dautzenberg FM; Higelin J; Pflieger P; Neidhart W; Guba W
    Neuropharmacology; 2005 Jun; 48(7):1043-55. PubMed ID: 15857631
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The first highly potent and selective non-peptide neuropeptide Y Y1 receptor antagonist: BIBP3226.
    Rudolf K; Eberlein W; Engel W; Wieland HA; Willim KD; Entzeroth M; Wienen W; Beck-Sickinger AG; Doods HN
    Eur J Pharmacol; 1994 Dec; 271(2-3):R11-3. PubMed ID: 7705422
    [TBL] [Abstract][Full Text] [Related]  

  • 35. BIIE0246: a selective and high affinity neuropeptide Y Y(2) receptor antagonist.
    Doods H; Gaida W; Wieland HA; Dollinger H; Schnorrenberg G; Esser F; Engel W; Eberlein W; Rudolf K
    Eur J Pharmacol; 1999 Nov; 384(2-3):R3-5. PubMed ID: 10611450
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neuropeptide Y induces gonadotropin-releasing hormone gene expression directly and through conditioned medium from mHypoE-38 NPY neurons.
    Dhillon SS; Gingerich S; Belsham DD
    Regul Pept; 2009 Aug; 156(1-3):96-103. PubMed ID: 19371763
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Design, synthesis and evaluation of a novel cyclohexanamine class of neuropeptide Y Y1 receptor antagonists.
    Cho K; Ando M; Kobayashi K; Miyazoe H; Tsujino T; Ito S; Suzuki T; Tanaka T; Tokita S; Sato N
    Bioorg Med Chem Lett; 2009 Aug; 19(16):4781-5. PubMed ID: 19596193
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synthesis, radiolabeling, and preliminary biological evaluation of [3H]-1-[(S)-N,O-bis-(isoquinolinesulfonyl)-N-methyl-tyrosyl]-4-(o-tolyl)-piperazine, a potent antagonist radioligand for the P2X7 receptor.
    Romagnoli R; Baraldi PG; Pavani MG; Tabrizi MA; Moorman AR; Di Virgilio F; Cattabriga E; Pancaldi C; Gessi S; Borea PA
    Bioorg Med Chem Lett; 2004 Nov; 14(22):5709-12. PubMed ID: 15482953
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synthesis and evaluation of substituted 4-alkoxy-2-aminopyridines as novel neuropeptide Y1 receptor antagonists.
    Sato N; Shibata T; Jitsuoka M; Ohno T; Takahashi T; Hirohashi T; Kanno T; Iwaasa H; Kanatani A; Fukami T
    Bioorg Med Chem Lett; 2004 Apr; 14(7):1761-4. PubMed ID: 15026066
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Design, synthesis, and biological evaluation of substituted 2-cyclohexyl-4-phenyl-1H-imidazoles: potent and selective neuropeptide Y Y5-receptor antagonists.
    Blum CA; Zheng X; De Lombaert S
    J Med Chem; 2004 Apr; 47(9):2318-25. PubMed ID: 15084130
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.